What Interface Clinical Services does

Interface Clinical Services is a UK-based clinical services provider that employs more than 200 Clinical Pharmacists operating nationally to support NHS primary care, with its head office in Horsforth/Yeadon, Leeds. The company delivers pharmacist-led clinical reviews across long-term conditions (asthma, COPD, atrial fibrillation, diabetes, bone health, heart failure, lipid management, and cardiovascular disease), supports Quality and Outcomes Framework (QOF) achievement and disease register maintenance, and works with GP practices, Primary Care Networks (PCNs), Integrated Care Boards (ICBs), and Clinical Commissioning Groups across England. Interface holds NHS Business Partner status, completes the NHS Data Security and Protection Toolkit annually, and supports over 1,500 GP practices annually—approximately 50% of England's GP practices in the last two years.

The core technology stack is the proprietary Attend2 platform suite (Attend2 AF, Asthma, COPD, Diabetes, Fracture, Heart Failure, Lipids, and CVD Indicators), the QOF Disease Prevalence Platform covering all 20 QOF clinical domains with a Heart Failure Plus tool, and the IMPACT CVD Suite, which combines IMPACT CVD Prevalence and Attend2 CVD Indicators with clinical mentorship. These platforms run patient searches and stratification logic across the two dominant UK GP clinical systems (SystmOne and EMIS), using QOF-recognised codes to identify uncoded or under-coded patients and to segment caseloads by clinical risk and staff capacity. The output is combined with on-site and remote pharmacist delivery, structured consultancy days, mentoring, and revalidation reports that track progress against QOF indicators.

Interface operates as a wholly-owned subsidiary of IQVIA (NYSE: IQV) and generates revenue from three streams: (i) professional clinical services to NHS organisations (practices, PCNs, and ICBs) covering therapy reviews, coding and QOF consultancy, and quality improvement programmes; (ii) industry partnership services for pharmaceutical and biotech companies including market access, data services, remote services, and regulatory support; and (iii) recurring software subscriptions to Attend2, IMPACT CVD, and the QOF Disease Prevalence Platform, with listed annual subscription pricing ranging from approximately £1,000 to £4,717 per module and £717 per consultancy day, plus VAT. Distribution is primarily through a UK field-based Clinical Pharmacist workforce with website-led e-commerce and direct NHS partnership channels, supported by conferences (RCGP, PCRS, NICE), peer-reviewed publications (BMJ Open, QJM), and industry awards (multiple HSJ Partnership Awards shortlists).

Name

Interface Clinical Services

Legal name

Interface Clinical Service Ltd

Website

https://interface-cs.co.uk

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Clinical Pharmacy Services

NAICS

All Other Outpatient Care Centers (621498)

SIC

Services-Health Services (8000)

akta.pro primary industry

Virtual Pharmacy & Medication Management Integration Platforms (HLALABAL)

akta.pro secondary industries

Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored) (HLALACAK), Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD), Patient Access Programs & Affordability (Copay/Hubs/PSP) (HLAIAKAG)

Keywords

• Clinical pharmacy services
• NHS primary care
• QOF disease prevalence
• Therapy review services
• Pharmacist-led programmes

Headquarters

HQ city

Yeadon

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Services to NHS: Interface delivers pharmacist-led clinical services to GP practices, PCNs, and ICBs across the UK. Services include therapy reviews (asthma, COPD, AF, diabetes, bone health, heart failure, etc.), QOF disease prevalence support, and Attend2 platform subscriptions. Services are purchased by NHS organisations and can be funded at no additional cost to practices through partnership arrangements.
2. Industry Partnership Services: Interface works with pharmaceutical and biotech companies to deliver market access, data services, remote services, and regulatory compliance support. These services help industry partners engage with the NHS, demonstrate product value through real-world evidence data, and support market access strategies.
3. Software Platform Subscriptions: Attend2 platforms (Attend2 AF, Attend2 Asthma, Attend2 COPD, Attend2 Diabetes, Attend2 Fracture, Attend2 Heart Failure, Attend2 Lipids, Attend2 CVD Indicators) and QOF Disease Prevalence Platform are available as purchased subscriptions. Each platform has tiered pricing with optional add-ons such as consultation days, data refreshes, and mentoring.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Interface Clinical Services provides pharmacist-led clinical services and proprietary patient management software to NHS GP practices, Primary Care Networks, and Integrated Care Boards across the UK. Its core offering combines over 200 employed Clinical Pharmacists who deliver on-site and remote therapy reviews (asthma, COPD, AF, diabetes, bone health, heart failure, lipid management, etc.) with the Attend2 clinical platforms and the QOF Disease Prevalence Platform covering all 20 QOF domains. The IMPACT CVD Suite bundles cardiovascular prevalence and indicator tools with mentorship to drive CVD outcomes and QOF achievement.

Product overview

Interface Clinical Services operates as a platform-plus-services company offering clinical pharmacist support to the NHS and primary care. The core offering consists of the Attend2 patient management platforms (Attend2 AF, Attend2 Asthma, Attend2 COPD, Attend2 Diabetes, Attend2 Fracture, Attend2 Heart Failure, Attend2 Lipids, Attend2 CVD Indicators) and the QOF Disease Prevalence Platform covering all 20 QOF domains with Heart Failure Plus tools. These platforms are complemented by therapy review services (Asthma, COPD, AF, Diabetes, Bone Health, Heart Failure, Lipid Management, Blood Glucose Testing, Pen Needle, Malnutrition, Continence, Stoma) and the IMPACT CVD Suite combining prevalence and indicator tools with mentorship. The IMPACT CVD Suite (including IMPACT CVD Prevalence and Attend2 CVD Indicators modules) represents the company's flagship cardiovascular disease prevention solution. Additional services include QOF Consultancy Days, Coding Days, Revalidation Reports, and the structured Disease Prevalence Quality Improvement Programme delivered over 4 phases.

Differentiator

Problem solved

Functional benefit

Brands

• IMPACT CVD Suite: Platform combining intelligent platforms with expert mentorship to help primary care teams deliver cardiovascular outcomes
• Attend2
• Interface Academy

Products and services

• IMPACT CVD Suite Comprehensive cardiovascular disease prevention platform combining IMPACT CVD Prevalence and Attend2 CVD Indicators with expert mentorship to help primary care teams deliver NHS CVD priorities, close care gaps, and achieve QOF indicators.
• QOF Disease Prevalence Platform Core platform covering all 20 QOF domains with Heart Failure Plus tool, enabling practices to identify patients missing from disease registers and track progress with revalidation reports.
• Attend2 AF Proactive risk management tool highlighting specific cohorts of at-risk atrial fibrillation patients to reduce the incidence of stroke through comprehensive stratification.
• Attend2 Asthma Clinical platform supporting the systematic management of patients with asthma in line with BTS/SIGN guidelines.
• Attend2 COPD Platform for proactive and systematic management of COPD patients to reduce symptoms and risk of exacerbations.
• Attend2 Diabetes Risk-stratification platform for primary care enabling systematic management of diabetes patients to reduce complications including cardiovascular disease.
• Attend2 Fracture Proactive fracture risk assessment tool (FRAX) for GP practices to identify patients at risk of osteoporotic fracture per NICE CG146.
• Attend2 Heart Failure Platform supporting the management of heart failure patients with increasing prevalence, helping improve quality of life and reduce NHS costs.
• Attend2 Lipids Clinical platform supporting management of patients with cardiovascular disease or those at risk of CVD through lipid management.
• Asthma Therapy Review Pharmacist-led review service to optimise asthma management, improve inhaler technique, and reduce urgent care episodes.
• COPD Therapy Review Systematic management of COPD patients to reduce symptoms, exacerbations, and emergency hospital admissions.
• Atrial Fibrillation Support Stroke prevention service through effective anticoagulation and DOAC therapy optimisation for AF patients.
• Diabetes Therapy Review Clinical assessment and management optimisation for diabetes patients to improve achievement of NICE-recommended nine key care processes.
• Bone Health Therapy Review Support for osteoporosis and fragility fracture patients to ensure management in line with best practice guidelines.
• Heart Failure Therapy Review Specialist heart failure management service with training, patient education, and British Heart Foundation literature provision.
• Lipid Management Support for primary care with lipid management for secondary prevention of atherosclerotic cardiovascular disease (ASCVD).
• Blood Glucose Testing Service Review service ensuring patients monitor blood glucose levels in line with NICE guidelines and practice-preferred meters.
• Pen Needle Review Review service to improve patient safety, injection technique, and prescribing optimisation for pen needles.
• Malnutrition Review Review service for malnourished or at-risk patients to improve management and reduce NHS burden through better nutrition.
• Continence Review Specialist nurse-led clinic service for continence patients delivered remotely with patient prioritisation.
• Stoma Review Specialist nurse-led clinic service for stoma patients with data extraction and patient prioritisation.
• Disease Prevalence Quality Improvement Programme 6-12 month structured programme with four phases covering CVD, respiratory/MSK, high dependency, and mental health/neurology domains, combining Attend2 platforms and QOF tools with pharmacist support.

Quantifiable outcome

• Over £17.6 million in additional QOF income generated for practices and PCNs with 214,846 patients added to QOF registers
• +6 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• Mid and South Essex Health and Care PartnershipcoreStrategic or Co-development Partner · 1 January 2021HSJ Partnership Awards 2021 shortlisted partnership for Pharmacist-Led Review of High-Risk Asthmatic Patients. The project provided additional support to patients with respiratory conditions during the COVID-19 pandemic, ensuring continuity of care and preventing non-COVID related unplanned primary and secondary care encounters.
• UCLPartnerscoreStrategic or Co-development PartnerInnovative collaboration announced between Interface Clinical Services (IQVIA) and UCLPartners to support the NHS in adopting a proactive, population health approach to managing long-term conditions. UCLPartners provides proactive care frameworks while Interface provides additional clinical capacity through trained pharmacists. The collaboration offers multidisciplinary teams increased access to mentorship, education, and training opportunities.
• Leeds Health and Care PartnershipcoreStrategic or Co-development PartnerHSJ Partnership Awards finalist collaboration focused on creating efficiencies in prescribing of Oral Nutritional Supplements (ONS) across Leeds. The project involved 65 practices and 2,540 patients, generating £397,887 in annual cost savings. Practice adherence to preferred ONS increased from 18.8% to 50.13%.
• Yorkshire & Humber Academic Health Science NetworkmajorStrategic or Co-development PartnerNew collaboration agreement signed between Yorkshire & Humber AHSN and Interface Clinical Services to deliver improved health and care services. Yorkshire & Humber AHSN focuses on health innovation to help people from North London to the Essex coast live longer, healthier lives.
• Mid & South Essex Health and Care Partnership (Respiratory)majorStrategic or Co-development PartnerInterface awarded a contract to deliver asthma support to Mid & South Essex Health and Care Partnership, providing additional clinical pharmacist resource to assess and proactively manage patients with asthma.
• Academic Health Science Network for the North East and North Cumbria (AHSN NENC)majorStrategic or Co-development PartnerInterface Bone Health Programme: A Proactive Population Approach to Bone Health was recognised on the NICE shared learning platform in partnership with AHSN NENC. The project was shortlisted for HSJ Partnership Awards 2020.
• Sentinel HealthcaremajorStrategic or Co-development PartnerSafe and effective management of stroke prevention in atrial fibrillation partnership recognised on NICE shared learning platform. Interface worked with Sentinel Healthcare GP Federation on AF management programme that was commended at Anticoagulation Achievement Awards.
• Slough CCGminorStrategic or Co-development PartnerSupporting the management of type 2 diabetes with pharmacist-led reviews and implementing NICE recommended nine key care processes, featured on NICE shared learning platform.
• NHS Leicester, Leicestershire and Rutland Integrated Care BoardmajorStrategic or Co-development PartnerJoint poster presentation at Primary Care Respiratory Society (PCRS) on pharmacist-led reviews to proactively manage patients with COPD and overcome the backlog of care. Programme provided additional clinical pharmacist resource to assess and proactively manage high-risk COPD patients.
• Isle of Wight CCGminorStrategic or Co-development PartnerInterface partnered with Isle of Wight CCG to help improve prescribing of pen needles across 16 practices covering 141,000 patients, implementing national pen needle guidance.
• Cheshire Merseyside STP / Health & Care Partnership for Cheshire & MerseysideminorStrategic or Co-development PartnerCase study on lipid management and statin therapy with Cheshire Merseyside STP. Interface created a Lipid Management Dashboard as part of the Lipid commissioning for value programme.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Soar Beyond: UK-based provider of clinical pharmacist services and training to NHS primary care. Directly comparable to Interface in deploying pharmacists into GP practices for therapy reviews and chronic disease management, making it the most like-for-like UK clinical pharmacy services competitor.
• Ardens Health Informatics: UK supplier of clinical templates, QOF searches, and patient management tools for EMIS and SystmOne GP practices. Directly comparable to Interface's Attend2 and QOF Disease Prevalence offerings in primary care clinical IT.
• Modus Partners: UK healthcare consultancy delivering clinical services, market access, and strategic programmes to the NHS and life sciences industry. Comparable to Interface's industry partnership arm and NHS-facing clinical programme work.

Broad incumbents

• EMIS Group: Provider of EMIS Web, the dominant UK GP clinical system used by the majority of NHS practices. Interfaces with Interface's Attend2/QOF tools and represents the primary platform incumbent on which Interface's services are delivered.
• TPP: UK health IT vendor behind SystmOne, the other dominant UK GP clinical system. As with EMIS, Interface's platforms and search tools integrate directly with SystmOne to deliver QOF and CVD reviews within practices.
• Practice Plus Group: Large UK healthcare provider delivering NHS clinical services across primary, secondary and urgent care. Comparable as a broad NHS clinical services incumbent that, like Interface, sells outsourced clinical capacity into the NHS.
• HCRG Care Group: Large UK provider of community, primary, and NHS clinical services (formerly Virgin Care). Comparable to Interface in delivering outsourced NHS clinical services at scale across multiple geographies.

Emerging players

• Spirit Healthcare: UK health company offering clinical services, diagnostics, and digital health products to the NHS. Comparable to Interface in combining clinical service delivery with proprietary products aimed at primary care.
• Outcomes Based Healthcare: UK company focused on population health management and outcomes-based commissioning for the NHS. Comparable to Interface's ICB-facing work on QOF, prevalence uplift, and CVD/population health programmes.

Regional players

• Totally plc: UK provider of NHS urgent care, planned care, and clinical services, including primary care-facing solutions. Comparable as a regional NHS clinical services provider competing for similar commissioner budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/InterfaceCS1

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interface Clinical Services